C4 Therapeutics, Inc.
NASDAQ: CCCC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew J. Hirsch
- Employees
- 110
- Headquarters
- Watertown, United States
- IPO year
- 2020
- Market cap
- $352.0M
- Website
- https://www.c4therapeutics.com
Loading CCCC…
Loading profile data…Frequently asked questions about CCCC
What does C4 Therapeutics, Inc. (CCCC) do?
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate...
Where does CCCC trade?
C4 Therapeutics, Inc. (CCCC) trades on the NASDAQ Global Select.
What sector is CCCC in?
C4 Therapeutics, Inc. (CCCC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of C4 Therapeutics, Inc.?
Andrew J. Hirsch is the chief executive officer of C4 Therapeutics, Inc. (CCCC).
Where is C4 Therapeutics, Inc. headquartered?
C4 Therapeutics, Inc. is headquartered in United States.
Does CCCC pay a dividend?
C4 Therapeutics, Inc. (CCCC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CCCC go public?
C4 Therapeutics, Inc. (CCCC) completed its initial public offering in 2020.